Statistics from Altmetric.com
Since the successful introduction of antivascular endothelial growth factor (VEGF) intravitreal injections (IVT) for the management of age-related macular degeneration (AMD), this treatment has gained popularity. Several studies have reported on the complications of anti-VEGF IVT, including a transient rise in intraocular pressure (IOP).1
We aimed to determine whether IOP measurement post-IVT is necessary following injection of the commonly used anti-VEGF agents: ranibizumab (Lucentis), bevacizumab (Avastin) and pegabtanib (Macugen).
This was a retrospective observational study of postinjection change in IOP in patients with neovascular AMD who received an injection of an anti-VEGF drug between September 2006 and March 2008. Patients were treated with one of three anti-VEGF drugs (ranibizumab 0.5 mg, bevacizumab 1.25 mg, pegabtanib 0.3 mg) using a sterile technique. Povidine iodine 5% preparation and topical oxybuprocaine anaesthetic …